Evaluation of a cyclic GMP-dependent protein kinase inhibitor in treatment of murine toxoplasmosis: gamma interferon is required for efficacy.
about
Changes in the expression of human cell division autoantigen-1 influence Toxoplasma gondii growth and developmentToxoplasma gondii cyclic GMP-dependent kinase: chemotherapeutic targeting of an essential parasite protein kinase.Activity of a trisubstituted pyrrole in inhibiting sporozoite invasion and blocking malaria infection.High-throughput growth assay for Toxoplasma gondii using yellow fluorescent protein.Toxoplasma on the brain: understanding host-pathogen interactions in chronic CNS infection.Toxoplasma gondii: determinants of tachyzoite to bradyzoite conversion.Protein palmitoylation and pathogenesis in apicomplexan parasites.The role of cGMP signalling in regulating life cycle progression of Plasmodium.Screening and synthesis: high throughput technologies applied to parasitology.Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity.Cyclic-nucleotide signalling in protozoa.Protein kinases of Toxoplasma gondii: functions and drug targets.Antiplasmodial drug targets: a patent review (2000 - 2013).Reduction of Toxoplasma gondii Development Due to Inhibition of Parasite Antioxidant Enzymes by a Dinuclear Iron(III) Compound.Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites.Cyclic nucleotide kinases and tachyzoite-bradyzoite transition in Toxoplasma gondii.Purification and molecular characterization of cGMP-dependent protein kinase from Apicomplexan parasites. A novel chemotherapeutic target.cGMP-dependent protein kinase from Toxoplasma gondii: functional expression in E. coli and molecular characterization.Effects of Estradiol and Progesterone-Induced Intracellular Calcium Fluxes on Toxoplasma gondii Gliding, Microneme Secretion, and Egress.
P2860
Q21131617-A28EBD53-3BBA-4F62-9D43-68825A384B54Q33904366-41E36970-04FE-4674-ABA5-991FEB8D24D2Q34151126-B91B9894-24F9-4349-BC57-58D1E33D7C71Q34725225-277A44DE-5F3A-4017-90F8-3EA354AB41B2Q35876115-267A08A0-5AD2-4316-B7BD-CB3A4A85439CQ35892079-9702231B-910C-4535-91B3-FA607B2CAB55Q36316026-57B8EBC5-1533-437F-BEFF-98429678B7BBQ36357666-C271403D-54F2-409B-9139-2535C764E94FQ36385090-E54DAAEB-4FEE-48CB-918E-35CA9BAD9674Q37428599-AF5E7BD6-C094-4D35-82CE-84968337BD41Q37827560-A2F7BE65-1A2B-4AEC-BC22-C32214AB2E79Q38107395-5AFCBF83-1EDB-4F1A-B86D-720A52615132Q38632903-7A024BE7-86DB-4E84-8CDC-46A1BA13FFE7Q38833635-CA18F9DA-649D-431A-BBE4-53887747A961Q40174344-12DB219B-6484-4F7A-8CF4-B9710677F453Q41808290-FE9889D6-006A-4445-9A5C-8908B7D5C5CAQ42162203-0CEC9E1A-E74E-4ABB-9A8C-26D3212B8C5DQ45928762-B65CB85A-0C63-45B4-916E-60B2A722FC0DQ55340188-143D24B3-51A8-4B52-A326-CD9BF48577CF
P2860
Evaluation of a cyclic GMP-dependent protein kinase inhibitor in treatment of murine toxoplasmosis: gamma interferon is required for efficacy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Evaluation of a cyclic GMP-dep ...... eron is required for efficacy.
@ast
Evaluation of a cyclic GMP-dep ...... eron is required for efficacy.
@en
Evaluation of a cyclic GMP-dep ...... eron is required for efficacy.
@nl
type
label
Evaluation of a cyclic GMP-dep ...... eron is required for efficacy.
@ast
Evaluation of a cyclic GMP-dep ...... eron is required for efficacy.
@en
Evaluation of a cyclic GMP-dep ...... eron is required for efficacy.
@nl
prefLabel
Evaluation of a cyclic GMP-dep ...... eron is required for efficacy.
@ast
Evaluation of a cyclic GMP-dep ...... eron is required for efficacy.
@en
Evaluation of a cyclic GMP-dep ...... eron is required for efficacy.
@nl
P2093
P2860
P1476
Evaluation of a cyclic GMP-dep ...... eron is required for efficacy.
@en
P2093
Bakela Nare
John J Allocco
Paul A Liberator
Robert G K Donald
P2860
P304
P356
10.1128/AAC.46.2.300-307.2002
P407
P577
2002-02-01T00:00:00Z